- 영문명
- Emicizumab Prophylaxis in Patients with Hemophilia A Undergoing Immune Tolerance Induction Therapy: A Systematic Review
- 발행기관
- 대한약학회
- 저자명
- 김아영 조윤 강서윤 박영실 백희조 이한길
- 간행물 정보
- 『약학회지』제67권 제2호(2023년), 75~84쪽, 전체 10쪽
- 주제분류
- 의약학 > 기타의약학
- 파일형태
- 발행일자
- 2023.04.30

국문 초록
영문 초록
Objective: The use of Emicizumab, a novel agent in hemophilia A, in patients with Hemophilia A undergoing immune tolerance induction (ITI) have been currently evolving in overseas. Here, we aimed to evaluate the real-world use and conceptual study of emicizumab use during ITI in patients with Hemophilia A. Methods: We searched PubMed, Embase, and Cochrane Library databases to perform systematic review according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA). Search terms include ‘hemophilia‘, ‘immune tolerance and ‘Emicizumab’. Hemophilia other than hemophilia A, studies with no relevant outcomes, emicizumab use other than during ITI were excluded. Results: Among 419 relevant studies, ten eligible studies were included in this review. Six studies reported real-world prophylactic use of emicizumab during ITI, and total of nineteen subjects, including overlapping patients, were evaluated. Other four studies reported conceptual study design of emicizumab in patients with hemophilia A undergoing ITI. Majority of study set the dose of emicizumab as 1.5mg/kg weekly or 3.0mg/kg bi-weekly after a loading dose of 3.0mg/kg for 4 weeks. In real-world prophylactic use studies, ITI outcome, inhibitor recurrence, antibody titer, adverse events, and FVIII activity were evaluated as outcomes. Conclusion: This study identified the current status of emicizumab use and made evidence for the applicability of emicizumab in patients with hemophilia A undergoing ITI.
목차
서 론(Introduction)
방 법(Methods)
결 과(Results)
고 찰(Discussion)
결 론(Conclusion)
감사의 말씀(Acknowledgment)
Conflict of Interest
References
해당간행물 수록 논문
참고문헌
최근 이용한 논문
교보eBook 첫 방문을 환영 합니다!
신규가입 혜택 지급이 완료 되었습니다.
바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!
